Evolus, Inc. (NASDAQ:EOLS) Given Average Rating of “Moderate Buy” by Brokerages

Evolus, Inc. (NASDAQ:EOLS) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $16.00.

A number of brokerages recently weighed in on EOLS. Mizuho set a $15.00 target price on shares of Evolus in a report on Wednesday, February 4th. Stifel Nicolaus dropped their price target on Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. HC Wainwright reduced their price objective on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Finally, BTIG Research restated a “buy” rating and issued a $13.00 target price on shares of Evolus in a report on Wednesday, March 4th.

Insider Buying and Selling at Evolus

In related news, insider David Moatazedi sold 10,539 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the transaction, the insider owned 354,388 shares in the company, valued at $2,533,874.20. This trade represents a 2.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.10% of the stock is owned by company insiders.

Institutional Trading of Evolus

Hedge funds have recently bought and sold shares of the company. Braidwell LP purchased a new position in Evolus during the fourth quarter valued at approximately $20,650,000. Frazier Life Sciences Management L.P. purchased a new stake in Evolus in the 2nd quarter worth approximately $22,431,000. Nantahala Capital Management LLC boosted its stake in shares of Evolus by 33.2% during the 3rd quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock valued at $35,163,000 after buying an additional 1,428,931 shares during the period. Soleus Capital Management L.P. boosted its stake in shares of Evolus by 96.4% during the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after buying an additional 1,039,842 shares during the period. Finally, Armistice Capital LLC purchased a new position in shares of Evolus during the 4th quarter valued at $6,490,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Trading Down 2.3%

Shares of NASDAQ EOLS opened at $5.53 on Monday. Evolus has a twelve month low of $4.09 and a twelve month high of $13.81. The company has a market capitalization of $359.78 million, a price-to-earnings ratio of -6.83 and a beta of 1.02. The firm has a 50-day moving average of $5.04 and a two-hundred day moving average of $6.21.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.09). The firm had revenue of $90.30 million for the quarter, compared to the consensus estimate of $89.58 million. As a group, research analysts predict that Evolus will post -0.61 earnings per share for the current year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.